Sangivamycin Explained

Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.[1] [2] [3] [4] [5] [6] [7]

Oyagen, a biotechnology company, has been developing sangivamycin or OYA1, which showed efficacy against Ebola infections,[8] as a broad spectrum antiviral for COVID-19.[9] [10] Tonix Pharmaceuticals licensed OYA1 from Oyagen in April 2021 to develop it for the treatment of COVID-19 and it is now called TNX-3500. [11] [12] [13]

See also

Notes and References

  1. Tolman RL, Robins RK, Townsend LB . Pyrrolo[2,3-d]pyrimidine nucleoside antibiotics. Total synthesis and structure of toyocamycin, unamycin B, vengicide, antibiotic E-212, and Sangivamycin (BA-90912) . Journal of the American Chemical Society . 90 . 2 . 524–6 . January 1968 . 5634627 . 10.1021/ja01004a076 .
  2. De Clercq E, Bernaerts R, Bergstrom DE, Robins MJ, Montgomery JA, Holy A . Antirhinovirus activity of purine nucleoside analogs . Antimicrobial Agents and Chemotherapy . 29 . 3 . 482–7 . March 1986 . 3013084 . 10.1128/aac.29.3.482 . 180418 . free .
  3. Loomis CR, Bell RM . Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C . The Journal of Biological Chemistry . 263 . 4 . 1682–92 . February 1988 . 10.1016/S0021-9258(19)77930-7 . 3338987 . free .
  4. Kučić N, Mahmutefendić H, Lučin P . Inhibition of protein kinases C prevents murine cytomegalovirus replication . The Journal of General Virology . 86 . Pt 8 . 2153–2161 . August 2005 . 16033962 . 10.1099/vir.0.80733-0 . free .
  5. Lee SA, Jung M . The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation . The Journal of Biological Chemistry . 282 . 20 . 15271–83 . May 2007 . 17371872 . 10.1074/jbc.M701362200 . free .
  6. Bastea LI, Hollant LM, Döppler HR, Reid EM, Storz P . Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death . Scientific Reports . 9 . 1 . 16588 . November 2019 . 31719634 . 10.1038/s41598-019-53223-0 . 6851150 . 2019NatSR...916588B . free .
  7. https://patents.google.com/patent/CA3040540A1 Smith HC, et al. Methods of treating and inhibiting ebola virus infection. Patent application CA3040540, Oyagen Inc, 17 May 2018
  8. Bennett RP, Finch CL, Postnikova EN, Stewart RA, Cai Y, Yu S, Liang J, Dyall J, Salter JD, Smith HC, Kuhn JH . 6 . A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures . Viruses . 13 . 1 . 52 . December 2020 . 33396288 . 7824103 . 10.3390/v13010052 . free .
  9. Web site: Philippidis A . 2020-05-18. OyaGen - OYA1. 2021-04-22. GEN - Genetic Engineering and Biotechnology News. en-US.
  10. Web site: Philippidis A . 2020-03-18. Catching Up to Coronavirus: Top 60 Treatments in Development. 2021-04-22. GEN - Genetic Engineering and Biotechnology News. en-US.
  11. Web site: Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact. 2021-04-22. FierceBiotech. 19 April 2021 . en.
  12. Web site: BioWorld Science. 2021-04-22. science.bioworld.com.
  13. Web site: Tonix Seeks to Advance OyaGen's COVID-19 Treatment Under New Global Licensing Deal. 2021-04-22. BioSpace. en-US.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sangivamycin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.